PRISM BioLab Co

PRISM BioLab Co Revenue

The The revenue of PRISM BioLab Co (206A.T) as of Nov 10, 2026 is 677.33 M JPY. In the previous year, The revenue was 305.62 M JPY — a change of 121.62% (higher).

Revenue

677.33 MJPY

YoY

121.62%

Last updated:

In 2025, PRISM BioLab Co's sales reached 677.33 M JPY, a 121.62% difference from the 305.62 M JPY sales recorded in the previous year.

Over the last 3 years PRISM BioLab Co grew revenue by 7.0% annually, reaching 676.76 M JPY.

The PRISM BioLab Co Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
Date
Revenue
Jan 1, 2022
554.40 M JPY
Jan 1, 2023
112.93 M JPY
Jan 1, 2024
305.62 M JPY
Jan 1, 2025
677.33 M JPY
Jan 1, 2026 (e)
0.00 JPY
The PRISM BioLab Co Revenue history
YEARRevenueYoY
est0.00JPY-100.00%
677.33 MJPY+121.62%
305.62 MJPY+170.64%
112.93 MJPY-79.63%
554.40 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PRISM BioLab Co Revenue

PRISM BioLab Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
552.54 M JPY
66.68 M JPY
72.96 M JPY
Jan 1, 2023
112.93 M JPY
-496.87 M JPY
-526.91 M JPY
Jan 1, 2024
292.12 M JPY
-782.39 M JPY
-1.05 B JPY
Jan 1, 2025
676.76 M JPY
-774.45 M JPY
-833.70 M JPY
Jan 1, 2026 (e)
0.00 JPY
0.00 JPY
0.00 JPY

PRISM BioLab Co Margins

PRISM BioLab Co stock margins

The PRISM BioLab Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PRISM BioLab Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PRISM BioLab Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
96.85 %
12.07 %
13.20 %
Jan 1, 2023
71.11 %
-439.99 %
-466.60 %
Jan 1, 2024
54.96 %
-267.83 %
-359.27 %
Jan 1, 2025
39.86 %
-114.44 %
-123.19 %
Jan 1, 2026 (e)
39.86 %
0.00 %
0.00 %

PRISM BioLab Co Stock analysis

What does PRISM BioLab Co do? PRISM BioLab Co Ltd generates revenue through two distinct business models in the pharmaceuticals sector. The in-house development business focuses on selecting drug discovery targets and creating programs internally using their PepMetics technology platform. The joint development business collaborates with pharmaceutical companies to develop drug discovery programs leveraging their proprietary PepMetics technology. Both models utilize the company's owned drug discovery platform to create new pharmaceutical products. The company's primary clients are pharmaceutical companies seeking to develop new drugs through partnerships with PRISM BioLab's technology. PRISM BioLab's business model centers on its PepMetics technology, which serves as the foundation for both its in-house development and joint development segments. The company builds new drug discovery platforms and develops new drugs through these segments, targeting pharmaceutical companies as their main customers. The firm's research and development activities are conducted using their owned technology, which differentiates their approach in the drug discovery market. The company's revenue streams are derived from pharmaceutical companies that partner with PRISM BioLab for drug discovery programs. By utilizing their PepMetics technology platform, the company creates targeted drug discovery solutions that are developed either internally or in collaboration with pharmaceutical partners. This approach allows PRISM BioLab to generate income through both direct development efforts and collaborative projects with industry clients. PRISM BioLab Co is one of the most popular companies on Eulerpool.

Revenue Details

Understanding PRISM BioLab Co's Sales Figures

The sales figures of PRISM BioLab Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing PRISM BioLab Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize PRISM BioLab Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in PRISM BioLab Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about PRISM BioLab Co stock

The revenue of PRISM BioLab Co is 677.33 M JPY in 2025.

The revenue of PRISM BioLab Co changed from 305.62 M JPY to 677.33 M JPY, representing a 121.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The revenue PRISM BioLab Co since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's PRISM BioLab Co historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — PRISM BioLab Co

All Key Metrics — PRISM BioLab Co